2024 |
Half-life extension via ABD-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation / J. Zhang, V. Bodenko, M. Larkina [et al.] // Journal of Controlled Release. – 2024. – Vol. 370. – P. 468-478. |
2024 |
Synthesis and Preclinical Evaluation of Urea-Based Prostate-Specific Membrane Antigen-Targeted Conjugates Labeled with 177Lu / A. E. Machulkin, S. A Petrov, V. Bodenko [et al.]. – DOI 10.1021/acsptsci.4c00070 // ACS Pharmacology and Translational Science. – 2024. – Vol. 7, No 5. – URL: https://pubs.acs.org/doi/10.1021/acsptsci.4c00070 (access date: 24.05.2024). |
2023 |
Боденко, В. В. Оценка интернализации in vitro таргетных терапетических препаратов, нацеленных на рецептор her-2 / В. В. Боденко // Фундаментальная наука и клиническая медицина - человек и его здоровье : Материалы XXVI Международной медико-биологической конференции молодых исследователей, Санкт-Петербург, 22 апреля 2023 года / Под редакцией А.М. Сараны [и др.]. Том XXVI. – Санкт-Петербург: Общество с ограниченной ответственностью Издательский дом «Сциентиа», 2023. – ISBN 978-5-6049390-4-8. – С. 675-676. |
2023 |
Synthesis, 123I-Radiolabeling Optimization, and Initial Preclinical Evaluation of Novel Urea-Based PSMA Inhibitors with a Tributylstannyl Prosthetic Group in Their Structures / L. A. Hasnowo, M. S. Larkina, E. Plotnikov [et al.]. – DOI 10.3390/ijms241512206 // International Journal of Molecular Sciences. – 2023. – Vol. 24, No 15. – URL: https://www.mdpi.com/1422-0067/24/15/12206 (access date: 04.10.2023). |
2023 |
177Lu-labeled PSMA targeting therapeutic with optimized linker for treatment of disseminated prostate cancer; evaluation of biodistribution and dosimetry / A. Abouzayed, K. Seitova, F. Lundmark [et al.]. – DOI 10.3389/fonc.2023.1221103 // Frontiers in Oncology. – 2023. – V. 13. – URL: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1221103/full (access date: 14.03.2023). |
2022 |
Visualization of epithelial cell adhesion molecule-expressing renal cell carcinoma xenografts using designed ankyrin repeat protein Ec1 labelled with 99mTc and 125I / V. Tolmachev , V. Bodenko, A. Orlova [et al.]. – DOI 10.3892/ol.2022.13598 // Oncology Letters. - 2023. - V. 25. – URL: https://www.spandidos-publications.com/10.3892/ol.2022.13598 (access date: 12.07.2023). |